KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Before Oct 1, 2027 71%-15.0ptFührend unter 5 Optionen
Marktqualitat
33 / 100
Niedrige Qualität24h-Volumen
158,7 €
Liquidität
179,2 €
Niedrige LiquiditätSpread
8.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 10 Minuten
19. Aug. 26, 22:001. Okt. 27, 3:59
Trends
0%
0%
0%
0%
Regeln
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.
Settles via:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Häufige Fragen
- Wie stehen die aktuellen Quoten für Will the FDA approve intismeran autogene (V940/mRNA-4157)??
- Kalshi bewertet Before Oct 1, 2027 mit 71% (Stand: 24. August 2026).
- Wann wird Will the FDA approve intismeran autogene (V940/mRNA-4157)? entschieden?
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? soll am 1. Oktober 2027 entschieden werden.
- Wie wird Will the FDA approve intismeran autogene (V940/mRNA-4157)? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.
